Uganda National Cervical Cancer Screening and Precancer Treatment Guidelines

Objectives

Uganda’s cervical cancer screening guidance seeks to reduce preventable cervical cancer incidence, morbidity and mortality through vaccination, organised screening, early detection, prompt diagnosis, treatment of precancerous lesions, referral and follow-up across the life course.[1][2]It responds to low, largely opportunistic screening coverage and late presentation, with more than 80% of women reportedly diagnosed at stage 3 or 4.[1]The guidelines support national cancer-control priorities and contribute to the global elimination ambition of vaccinating 90% of eligible girls by age 15, screening 70% of eligible women at least twice during their lifetime, and treating at least 90% of women with positive screening tests or cervical lesions.[3][2]

• Standardise screening, precancer treatment, referral and operational protocols across levels of care, while supporting patient-centred and individualised care.[3][4]
• Prioritise human papillomavirus, or HPV, testing as the primary screening method, using visual inspection with acetic acid, or VIA, where HPV testing is unavailable or loss to follow-up is a concern, and cytology in specified circumstances.[5][6]
• Target women in the general population principally between ages 30 and 49 years, women living with HIV between ages 25 and 49 years, and previously unscreened women aged 50 to 65 years who remain at risk.[5][7]
• Expand coverage progressively towards at least 70% of women in the target age group within 10 years of programme initiation, with every eligible woman screened at least once when the greatest benefit can be achieved.[8][6]
• Prevent progression to invasive disease by identifying and treating high-risk HPV infection and precancerous lesions before cancer develops.[8]
• Maintain screening for women who received HPV vaccination, since vaccination reduces future risk but does not remove the need for screening at eligible ages.[8]

Implementation

The delivery model is an organised, integrated screen-and-treat continuum linking community mobilisation and systematic invitation with screening, diagnosis, referral, treatment, follow-up, quality assurance and monitoring.[8][5]Screening programmes should be introduced according to service capacity and only where trained personnel, equipment, confirmatory diagnosis and treatment are available.[8]Selection of screening and treatment methods should take account of the risk of loss to follow-up, costs, equipment and human-resource availability.[3][6]

• Deliver HPV testing through self-collected or provider-collected samples, including community or household self-sampling through village health teams where feasible.[9][10]
• Provide VIA and sample collection at Health Centre III level, with thermal ablation capacity, and provide sample collection, thermal ablation and loop electrosurgical excision procedure, or LEEP, at Health Centre IV and hospital levels.[10]
• Apply a screen-and-treat pathway by assessing HPV-positive women for eligibility for ablative treatment, offering thermal ablation or cryotherapy where eligible, and referring women ineligible for ablation for LEEP, further evaluation or specialist management.[7]
• Refer suspected invasive cancer immediately for diagnostic confirmation and further management, and train providers to recognise suspected invasive disease during screening.[11][12]
• Use same-day treatment for screen-positive women with eligible lesions where possible to reduce loss to follow-up and improve treatment completion.[13][14]
• Provide cytology only where the system can support specimen collection, labelling, transport, microscopy, skilled laboratory personnel and associated logistics.[13][6]
• Adapt services for special populations by initiating screening at diagnosis for women living with HIV or other immunosuppression with prior sexual exposure, deferring routine screening during pregnancy unless symptoms are suspicious, and resuming screening three months after delivery or abortion.[10]
• Use five-year intervals after a negative HPV test in the general population, three-year intervals after a negative VIA test, and more frequent HPV follow-up for women living with HIV or women with positive results as specified in the pathway.[5][9][13]
• Ensure that trained nurses, midwives, clinical officers, medical officers, doctors and gynaecologists undertake procedures appropriate to their cadre, facility level and required technical skills.[4][10]
• Coordinate implementation under Ministry of Health leadership with health facilities, specialised hospitals, academic institutions, civil-society and cancer organisations, and development and technical partners including the World Health Organization, United States Agency for International Development, United Nations Population Fund, Makerere University, Uganda Cancer Institute, PATH and the Clinton Health Access Initiative.[3]
• Maintain quality control, quality assurance, provider supervision, updated training, adequate infrastructure, health education, advocacy and resource mobilisation throughout the service continuum.[8][9]
• Monitor screening, positivity and treatment rates through the Health Management Information System quarterly and annually; assess coverage through representative household surveys, including approximately five-yearly Uganda Demographic and Health Survey measurement; and measure age-specific incidence through population-based or sentinel hospital-based cancer registries.[14][15]
• Track same-day treatment, completion of referred treatment and appropriate treatment or follow-up for suspected invasive cancer, recognising that incidence and mortality reductions may take a decade to become evident.[12]

Monitoring & Evaluation

The guidelines establish a monitoring and evaluation framework for cervical cancer screening that connects service performance, treatment completion, population coverage and disease impact. Monitoring is intended to support supervision, quality improvement, corrective action and local problem-solving through health-information systems and engagement of providers and communities.[16]

• Monitor screening rate, screen-test positivity and treatment rate quarterly and annually, using numerator and denominator data recorded through the Health Management Information System (HMIS) at facility or centralised level.[14][15]
• Measure screening rate as the proportion of eligible women screened for the first time during a defined period, including the previous 12 months for visual inspection with acetic acid indicators.[16][14]
• Use positivity trends to identify potential provider-training or quality concerns where results are unusually low or high.[14]
• Measure treatment rate as the proportion of women with positive screening results who receive appropriate treatment, with a proposed target of at least 90% of screen-positive women and women with invasive cancer receiving treatment.[14][15]
• Track same-day treatment for women with treatment-eligible lesions, completion of adequate treatment following referral for lesions ineligible for ablative treatment, and completion of appropriate treatment or follow-up for suspected invasive cancer.[12]
• Assess coverage as screening at least once among women aged 25 to 49 years, using representative household surveys approximately every five years, potentially through the Uganda Demographic and Health Survey.[16][15]
• Monitor progress towards screening at least 70% of women in the target age group within 10 years of programme initiation.[8]
• Measure age-specific cervical cancer incidence through population-based or sentinel hospital-based cancer registries, with quarterly and annual reporting.[15][12]

Impact assessment should interpret early rises in reported incidence cautiously, as screening can initially identify previously undiagnosed prevalent cancers. Expected longer-term effects are earlier-stage diagnosis and a gradual decline in newly detected invasive disease, while reductions in incidence and mortality may take a decade to become evident.[12]

Quality assurance is integral to the screening and treatment continuum. The programme calls for functioning quality-control and quality-assurance systems, trained and supervised providers, and linkage from screening to diagnostic confirmation, referral, treatment and follow-up.[8][9]Screening without access to treatment is not expected to reduce cervical cancer incidence.[8]

Follow-up requirements include rescreening after one year following treatment for precancerous lesions, clinical review six weeks after treatment in specified pathways, and differentiated rescreening intervals based on screening method and HIV status.[9][13][17]Programme protocols, systematic invitations, supervision and referral linkages provide operational accountability, although the excerpts do not define a comprehensive institutional accountability hierarchy or sanctions for non-performance.[5]

An evaluation plan should specify responsibilities, services and resources to be assessed, methods, data needs, performance and impact indicators, corrective-action processes, and an implementation budget.[16]

Costing & Financing

Cost and resource availability are recognised as decision factors in selecting cervical cancer screening and treatment approaches, but the excerpts do not provide a total programme budget, unit costs, funding gap, financing allocation or quantified economic assumptions.[3][6]

• Consider cost alongside the risk of loss to follow-up, availability of equipment and human resources, and capacity for confirmatory diagnosis and treatment when selecting service models.[3][6]
• Justify programme expenditure by disease prevalence, demonstrated intervention effectiveness, and the availability of equipment, personnel, diagnostic services and treatment facilities.[8]
• Mobilise resources through advocacy and resource mobilisation as components of programme implementation.[8]
• Provide for the operational resources needed for service delivery, including trained personnel, facilities, equipment, diagnostic capacity, treatment capacity and referral systems.[4][8]
• Recognise that loop electrosurgical excision procedure requires electricity, local anaesthesia, colposcopy guidance and more highly skilled personnel than ablative treatment, without specifying associated financial values.[18]
• Include a budget for implementation of evaluation activities within the evaluation plan, although no amount is specified.[16]

The World Health Organization provided financial support for preparation of the guidelines.[3]The combined vaccination and screening strategy is described as cost-effective in several low- and middle-income countries, and prevention and earlier detection are expected to reduce morbidity and treatment costs; however, no Uganda-specific cost-effectiveness estimates or economic assumptions are supplied.[2]

Service-delivery choices also have resource implications. Human papillomavirus testing, visual inspection with acetic acid, cytology, thermal ablation, cryotherapy and excisional treatment require different combinations of laboratory capacity, supplies, equipment, infrastructure and skilled staff.[19][13][10]Cytology-based screening in particular requires specimen collection and transport, laboratory microscopy, skilled personnel and logistical capacity that may be difficult in low-resource settings.[13]

No explicit funding sources beyond World Health Organization support for guideline preparation, nor a detailed resource-mobilisation plan, programme financing mechanism, donor allocation, funding-gap estimate or monetary treatment cost, are specified in the supplied material.[3][14][15]